Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …

Over the past decades, adoptive transfer of T cells has revolutionized cancer
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …

The use of T cells reactive with intracellular tumor-associated or tumor-specific antigens has
been a promising strategy for cancer immunotherapies in the past three decades, but the …

Lassa virus infects hundreds of thousands of people each year across rural West Africa,
resulting in a high number of cases of Lassa fever (LF), a febrile disease associated with …

T cell receptors (TCRs) orchestrate cellular immunity by recognizing peptide antigens bound
and presented by major histocompatibility complex (MHC) proteins. Due to the TCR's central …

In order to develop effective adoptive T cell treatments for cancer, therapeutic optimization of
engineered CAR and TCR T cells is crucial, by simultaneously focusing on intrinsic and …

Development of T cell receptors (TCRs) as immunotherapeutics is hindered by inherent TCR
cross-reactivity. Engineering more specific TCRs has proven challenging, as unlike …

近年来, 工程化T 细胞治疗在肿瘤免疫治疗领域取得了重大进展. 工程化T 细胞治疗主要包括T
细胞受体基因工程T 细胞(T-cell receptor-engineered T cell, TCR-T) 疗法和嵌合抗原受体T …